DRG Epidemiology’s coverage of glaucoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of glaucoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered.
DRG Epidemiology’s glaucoma forecast will answer the following questions:
Of all people with glaucoma, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of glaucoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following glaucoma subpopulations:
Total prevalent cases of glaucoma.
Primary (primary open-angle glaucoma and primary angle closure glaucoma) and secondary glaucoma subpopulations.
Prevalence of Glaucoma per 100 Among People Aged 40+ in 2019 and 2039
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Glaucoma over the Next 20 Years
Analysis of the Prevalent Cases of Glaucoma in 2019 by Subtype
Analysis of the Prevalent Cases of Glaucoma in 2019 by Diagnosis Status
Total Prevalent Cases of Glaucoma
Total Prevalent Cases of Primary Glaucoma
Total Prevalent Cases of Primary Open-Angle Glaucoma
Total Prevalent Cases of Primary Angle Closure Glaucoma
Total Prevalent Cases of Secondary Glaucoma
Diagnosed Prevalent Cases of Glaucoma
Studies Included in the Analysis of Glaucoma
Studies Excluded from the Analysis of Glaucoma
Risk/Protective Factors for Glaucoma
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.